On May 29, 2018 Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, reported that Isaac Ciechanover, M.D., the Company’s President and Chief Executive Officer, will participate at two upcoming investor conferences in June (Press release, Atara Biotherapeutics, MAY 29, 2018, View Source [SID1234526936]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2018 Global Healthcare Conference
Company Presentation: Tuesday, June 5, 2018 at 11:00 a.m. ET
Grand Hyatt in New York, NY

Goldman Sachs 39th Annual Global Healthcare Conference
Fireside Chat: Tuesday, June 12, 2018 at 1:20 p.m. PT
Terranea Resort in Rancho Palos Verdes, CA

Live audio webcasts of the presentations will be available by visiting the Investors section of the Atara website at www.atarabio.com. Archived replays of the webcasts will be available on the Company’s website for 14 days following each presentation.

On May 29, 2018 Sesen Bio, Inc. (Nasdaq: SESN), a late-stage clinical company developing next-generation antibody-drug conjugate therapies for the treatment of cancer, reported that Stephen Hurly, president and chief executive officer of Sesen Bio, will present a company overview at the Jefferies Global Healthcare Conference on Tuesday, June 5, 2018 at 8:30 a.m. ET in New York City (Press release, Eleven Biotherapeutics, MAY 29, 2018, View Source [SID1234526917]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the company’s presentation will be accessible from the Investors & Media section of Sesen Bio’s website, www.sesenbio.com. An archived replay of the webcast will be available on the company’s website for 90 days after the conference.

On May 29, 2018 Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases, reported that Isaac Ciechanover, M.D., the Company’s President and Chief Executive Officer, will participate at two upcoming investor conferences in June (Press release, Atara Biotherapeutics, 29 29, 2018, View Source [SID1234526936]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies 2018 Global Healthcare Conference
Company Presentation: Tuesday, June 5, 2018 at 11:00 a.m. ET
Grand Hyatt in New York, NY

Goldman Sachs 39th Annual Global Healthcare Conference
Fireside Chat: Tuesday, June 12, 2018 at 1:20 p.m. PT
Terranea Resort in Rancho Palos Verdes, CA

Live audio webcasts of the presentations will be available by visiting the Investors section of the Atara website at www.atarabio.com. Archived replays of the webcasts will be available on the Company’s website for 14 days following each presentation.

On May 29, 2018 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, reported that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 39th Annual Global Healthcare Conferenceon Tuesday, June 12, 2018at 8:40 am PT at the Terranea Resort, in Rancho Palos Verdes, CA (Press release, Arcus Biosciences, MAY 29, 2018, View Source [SID1234526921]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Individuals may access the live audio webcast by visiting the "Events & Presentations" section of the Company’s website at View Source A replay of the webcast will be available for 30 days following the live event.

On May 29, 2018 Genmab A/S (Nasdaq Copenhagen: GEN) reported that its CEO, Jan van de Winkel, Ph.D., will present a company update at the Goldman Sachs 39th Annual Global Healthcare Conference in Rancho Palos Verdes, California at 4:00 PM PDT on June 12, 2018 (1:00 AM CEST on June 13, 2018) (Press release, Genmab, MAY 29, 2018, View Source [SID1234527080]). A webcast of the presentation will be available on Genmab’s website at View Source

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!